nafamostat has been researched along with Ascites in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Ascites: Accumulation or retention of free fluid within the peritoneal cavity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miyasaka, Y | 1 |
| Ono, K | 1 |
| Nagayama, K | 1 |
| Murakami, T | 1 |
| Noguchi, O | 1 |
| Uchihara, M | 1 |
| Izumi, N | 1 |
| Miyake, S | 1 |
| Kubota, K | 1 |
| Enomoto, N | 1 |
| Tanaka, Y | 1 |
| Marumo, F | 1 |
| Sato, C | 1 |
1 other study available for nafamostat and Ascites
| Article | Year |
|---|---|
[A case of pancreatic pleural effusion and ascites treated successfully with conservative measures including octreotide and nafamostat mesilate].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ascites; Benzamidines; Drug Therapy, Combination; Gastroint | 1996 |